1. Home
  2. MTLS vs VNDA Comparison

MTLS vs VNDA Comparison

Compare MTLS & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Materialise NV

MTLS

Materialise NV

HOLD

Current Price

$7.77

Market Cap

431.6M

Sector

Technology

ML Signal

HOLD

Logo Vanda Pharmaceuticals Inc.

VNDA

Vanda Pharmaceuticals Inc.

HOLD

Current Price

$5.08

Market Cap

361.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MTLS
VNDA
Founded
1990
2002
Country
Belgium
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
431.6M
361.4M
IPO Year
2014
2005

Fundamental Metrics

Financial Performance
Metric
MTLS
VNDA
Price
$7.77
$5.08
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$14.90
AVG Volume (30 Days)
153.0K
635.3K
Earning Date
05-07-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$216,105,000.00
Revenue This Year
$6.38
$21.35
Revenue Next Year
$6.45
$37.40
P/E Ratio
$61.39
N/A
Revenue Growth
N/A
8.72
52 Week Low
$4.78
$4.27
52 Week High
$7.97
$9.91

Technical Indicators

Market Signals
Indicator
MTLS
VNDA
Relative Strength Index (RSI) 67.87 42.97
Support Level $6.37 $4.94
Resistance Level N/A $5.55
Average True Range (ATR) 0.24 0.18
MACD 0.04 -0.03
Stochastic Oscillator 80.61 17.14

Price Performance

Historical Comparison
MTLS
VNDA

About MTLS Materialise NV

Materialise NV is a provider of 3D-printed medical devices and software and a pioneer in additive manufacturing software and services. The company operates through three principal segments: Materialise Software, Materialise Medical, and Materialise Manufacturing, with the Materialise Medical segment generating maximum revenue. The Materialise Medical segment develops and delivers medical software solutions, medical devices, and related products and services; the Materialise Software segment develops and delivers additive manufacturing software solutions and related services; and the Materialise Manufacturing segment delivers 3D-printed products and related services. The company generates maximum revenue from the United States of America.

About VNDA Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.

Share on Social Networks: